KRSA
Korsana Biosciences, Inc. Health Care Pharmaceutical Preparations Russell 3000
$30.14Close
$115.2MMarket cap
$23.52 – $37.1952-week range
Nov 11, 2026Next report
Highlights
Cautions
- Results soon Nov 11, 2026, in 10 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
19%
1wk
down 3.7%
price change
1mo
down 5.8%
price change
12-month return
up 10%
total, dividends included
F-score
—
— Not assessed
Altman Z
37.79
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
12.7×
price / book
Earnings yield
down 4.4%
EBIT / enterprise value
Cheaper than
14%
of the market · expensive
Revenue growth
up 4%
year on year
EPS growth
—
latest quarter
Sales growth
down 100%
latest quarter · +0 pts
ROE
down 39%
return on equity
Free cash margin
down 160%
-$3.3M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
8.9%
$2.68 a day · 2×ATR $24.77
RS
—
vs the universe
Trend
—
trend template
Relative volume
1.2×
vs 50-day average
Up/down volume
1.02
50 sessions
Implied move
—
no option chain · report Nov 11, 2026
Contractions
2
22% → 17%
Pivot
$35.34
14.7% below
Volume dry-up
2.0×
10 vs 50 sessions
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 50.1% over the year, from 3m to 4m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Sep 11, 2026
Results reaction
Sep 11, 2026+28% vs market2 sessions after results
Financials
- Net -170%
- Free cash -160%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.3M | $3.9M | $297,000 | $0 | $2.0M | $2.1M |
| Operating income | -$81.3M | -$55.2M | -$18.5M | -$13.0M | -$3.6M | -$5.0M |
| Net income | -$77.8M | -$51.6M | -$44.1M | -$5.3M | -$3.1M | -$3.5M |
| Net margin | -3389% | -1310% | -14841% | — | -153% | -170% |
| Earnings per share | — | -$1.32 | -$20.28 | -$2.25 | -$1.21 | -$1.11 |
| Free cash flow | -$74.0M | -$36.5M | -$40.6M | -$21.2M | -$4.3M | -$3.3M |
| Free cash margin | -3224% | -927% | -13674% | — | -217% | -160% |
| Cash | $54.4M | $54.0M | $13.4M | $7.6M | $3.2M | $3.2M |
| Shareholders' equity | $59.5M | $48.2M | $10.5M | $11.3M | $8.8M | $9.1M |
| Shares outstanding | 34.05m | 43.41m | 2.18m | 2.47m | 2.55m | 3.82m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 12, 2026 | Quarterly ↗ | Mar 31, 2026 | 42d |
| Mar 30, 2026 | Annual ↗ | Dec 31, 2025 | 89d |
| Nov 12, 2025 | Quarterly ↗ | Sep 30, 2025 | 43d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Mar 4, 2025 | Annual ↗ | Dec 31, 2024 | 63d |
| Nov 14, 2024 | Quarterly ↗ | Sep 30, 2024 | 45d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Mar 5, 2024 | Annual ↗ | Dec 31, 2023 | 65d |
| Nov 13, 2023 | Quarterly ↗ | Sep 30, 2023 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 11, 2026 | Material agreement · Acquisition or disposal · Results · Unregistered share sale · Holder rights changed · Change of control · Director or officer change · Charter or bylaws · Item 5.05 · Item 5.06 · Regulation FD ↗ |
| Aug 27, 2026 | Shareholder vote · Other events ↗ |
| Aug 25, 2026 | Other events ↗ |
| Apr 1, 2026 | Material agreement · Change of control · Director or officer change · Regulation FD ↗ |
| Feb 17, 2026 | Regulation FD ↗ |
| Jan 6, 2026 | Material agreement · Regulation FD ↗ |
| Dec 1, 2025 | Other events ↗ |
| Sep 23, 2025 | Material agreement · Regulation FD ↗ |
| Jun 18, 2025 | Shareholder vote ↗ |
| May 7, 2025 | Material agreement ↗ |
| Mar 25, 2025 | Material agreement · Unregistered share sale ↗ |
| Dec 17, 2024 | Material agreement · Regulation FD ↗ |